Relationship between 18F-FDG PET/CT scans and KRAS mutations in metastatic colorectal cancer

Journal of Nuclear Medicine

Volumn 56, Issue 9, 2015, Pages 1322-1327

  Kawada, Kenji ^a   Toda, Kosuke ^a   Nakamoto, Yuji ^a   Iwamoto, Masayoshi ^a   Hatano, Etsuro ^a   Chen, Fengshi ^a   Hasegawa, Suguru ^a   Togashi, Kaori ^a   Date, Hiroshi ^a   Uemoto, Shinji ^a   Sakai, Yoshiharu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

18F FDG PET CT; Genetics; Imaging; KRAS; Metastatic colorectal cancer

Indexed keywords

DNA; FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; GENETIC MARKER; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RADIOPHARMACEUTICAL AGENT; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER SIZE; COLORECTAL SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; DRUG ACCUMULATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PET-CT SCANNER; PHARMACOLOGICAL PARAMETERS; POLYMERASE CHAIN REACTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; TREATMENT RESPONSE; COLORECTAL NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; GENETIC MARKER; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; MUTATION; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; GENETIC MARKERS; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS; RADIOPHARMACEUTICALS; RAS PROTEINS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84941013676     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.160614     Document Type: Article

References (26)

1. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
2. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
3. Baldus SE, Schaefer K-L, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16:790-799.
4. Albanese I, Scibetta AG, Migliavacca M, et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004;325:784-791.
5. Molinari F, Martin V, Saletti P, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer. 2009;100:1087-1094.
6. Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med. 2009;50:1820-1827.
7. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555-1559.
8. Kawada K, Nakamoto Y, Kawada M, et al. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res. 2012;18:1696-1703.
9. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123:3664-3671.
10. Iwamoto M, Kawada K, Nakamoto Y, et al. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. J Nucl Med. 2014;55:2038-2044.
11. Miles KA, Ganeshan B, Rodriguez-Justo M, et al. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. J Nucl Med. 2014;55:386-391.
12. Chen SW, Chiang HC, Chen WT, et al. Correlation between PET/CT parameters and KRAS expression in colorectal cancer. Clin Nucl Med. 2014;39:685-689.
13. Caicedo C, Garcia-Velloso MJ, Lozano MD, et al. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced nonsmall- cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41:2058-2065.
14. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945.
15. Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011;16:1239-1249.
16. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27: 2091-2096.
17. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379.
18. Etienne-Grimaldi MC, Formento JL, Francoual M, et al. K-ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14:4830-4835.
19. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13:1270-1275.
20. Suenaga Y, Kitajima K, Aoki H, et al. Respiratory-gated 18F-FDG PET/CT for the diagnosis of liver metastasis. Eur J Radiol. 2013;82:1696-1701.
21. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25:317-322.
22. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49:24S-42S.
23. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med. 2008;49: 43S-63S.
24. Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005;23:8713-8716.
25. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1: interaction between H-ras and hypoxia. J Biol Chem. 2001;276:9519-9525.
26. Kikuchi H, Pino MS, Zeng M, Shirasawa S, Chung DC. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1a and -2a in colon cancer. Cancer Res. 2009;69:8499-8506.